Advancing a New Class of Medicines

Company to Watch – NeuBase Therapeutics In the second of four features on NeuBase Therapeutics, Big4Bio spoke with Founder and CEO Dietrich Stephan and CFO Todd Branning about the company’s precision genetic medicine technology and pipeline, partnering and financing activities, and plans moving forward. By Marie Daghlian Todd Branning, chief financial officer of NeuBase Therapeutics, […]

Read More

The Big4Bio Company to Watch Program
April 2022: NeuBase Therapeutics

  THE COMPANY Drugging the Genome The spark behind NeuBase’s founding, and how the company is drugging the genome with precision genetic medicine.     THE TECHNOLOGY Advancing a New Class of Medicines Founder and CEO Dietrich Stephan and CFO Todd Branning talk about the company’s precision genetic medicine technology and pipeline.       […]

Read More

Drugging the Genome

Company to Watch – NeuBase Therapeutics In the first of four features on NeuBase Therapeutics, Big4Bio spoke with Founder and CEO Dietrich Stephan and CFO Todd Branning about the spark behind founding of the company, and how it is drugging the genome with precision genetic medicine. The second feature will provide an in-depth focus on […]

Read More